Welcome to Crossbow Therapeutics, the groundbreaking startup that has raised an impressive $80 million in Series A funding. Founded by visionary Geraldine Paulus, Crossbow Therapeutics is redefining the landscape of Biotechnology Research. With esteemed investors like Eli Lilly and Company, Polaris Partners, Pfizer, and MPM BioImpact, our mission is to revolutionize the reach of cancer treatment. At Crossbow Therapeutics, we are determined to cure cancer. Our passionate team is working tirelessly to create a powerful arsenal of therapeutics that will expand the reach and impact of antibodies used in cancer treatment. Our goal is to develop precise therapies capable of targeting the entire universe of cancer antigens.

Inspired by the precision and power of a crossbow, our next-generation therapies are aptly named T-Bolt molecules. With unparalleled accuracy and potency, these molecules strike tumor cells, just like a crossbow shoots bolts at its target. We envision a future where cancer is no longer a devastating diagnosis, but a conquerable challenge. Join us on our journey to revolutionize cancer therapy. At Crossbow Therapeutics, we are driven by a relentless commitment to innovation and a steadfast belief in the potential of precision medicine. Together, let's change the trajectory of cancer treatment and bring hope to countless lives around the world.